Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
11/2003
11/20/2003US20030215829 Nuclear hormone receptors
11/20/2003US20030215787 Modulators of the CLC-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215467 Isolated from resected and washed human gastrointestinal tract; for oral administration; probiotics
11/20/2003US20030215450 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
11/20/2003CA2823041A1 Fgf variants and methods for use thereof
11/20/2003CA2763775A1 Bisphosphonic acids for the treatment and prevention of osteoporosis
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2485527A1 Substituted pyrroline kinase inhibitors
11/20/2003CA2485083A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003CA2484770A1 Carbon monoxide as a biomarker and therapeutic agent
11/20/2003CA2484144A1 Eif-5a nucleic acids for inhibiting apoptosis
11/20/2003CA2483142A1 Use of vegf for treating bone defects
11/19/2003EP1362916A2 Human tumor necrosis factor delta and epsilon
11/19/2003EP1362911A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof
11/19/2003EP1362848A1 Process for the preparation of vitamin D derivatives
11/19/2003EP1362596A2 Inhibitor of stem cell proliferation and uses thereof
11/19/2003EP1362592A1 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kB
11/19/2003EP1362588A1 Medicinal compositions comprising diclofenac and ornoprostil
11/19/2003EP1362119A1 Glucosamine and method of making glucosamine from microbial biomass
11/19/2003EP1362108A2 Novel human protease and polynucleotides encoding the same
11/19/2003EP1362062A1 Concatameric immunoadhesion
11/19/2003EP1362061A2 Antibodies that bind both bcma and taci
11/19/2003EP1362054A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors
11/19/2003EP1362050A1 Pyrimidine derivatives for inhibition of cell-proliferation
11/19/2003EP1362048A1 Triazolo compounds as mmp inhibitors
11/19/2003EP1362046A1 Substituted pyrimidinone derivatives as ligands of integrin receptors
11/19/2003EP1362045A2 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
11/19/2003EP1362033A1 Pyridine matrix metalloproteinase inhibitors
11/19/2003EP1362031A1 Pharmaceutically active piperidine derivatives
11/19/2003EP1362028A2 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
11/19/2003EP1362027A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/19/2003EP1361882A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
11/19/2003EP1361880A2 6-substituted pyrido-pyrimidines
11/19/2003EP1361873A2 Matrix metalloproteinase inhibitors
11/19/2003EP1179005B1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/19/2003EP1017667B1 2-Amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
11/19/2003EP0973392B1 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
11/19/2003EP0809499B1 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
11/19/2003CN1457257A Extended native chemical ligation
11/19/2003CN1456345A Pillworm application for preparing medicine for treating osteoproliferation
11/19/2003CN1456319A Jingukang capsules for hyperosteogeny
11/19/2003CN1456315A Blood-activating bone-strengthening cream
11/19/2003CN1456313A Tiegudan for ischemic necrosis of fernoral head
11/19/2003CN1456273A Blood-activating ointment
11/19/2003CN1456272A Gouty ointment
11/19/2003CN1456256A Compound pseudo-ginseng preparing method
11/19/2003CN1456241A Method for preparing capsules against osteoproliferation
11/19/2003CN1456224A Preparation of spur eliminating capsules
11/19/2003CN1456208A Blood-activating cream
11/19/2003CN1456199A Chinese medicinal preparation for expelling wind and removing numbness and preparing method thereof
11/19/2003CN1456192A Natural bone density increasing elements
11/19/2003CN1456153A Preparing method for Xiatianwu alkaloids
11/19/2003CN1127978C Hyperosteogeny treating medicine
11/19/2003CN1127974C Chinese medicinal preparation for fracture
11/19/2003CN1127969C Medicinal spirit for hyperosteogeny
11/19/2003CN1127950C Antirheumatic agents
11/18/2003US6649657 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
11/18/2003US6649648 Administering 1-chroman, 1-thiochroman or quinoline derivative as anticarcinogenic or antimetastasis agent
11/18/2003US6649640 Isoxazole compositions useful as inhibitors of ERK
11/18/2003US6649636 Cyclooxygenase inhibitors
11/18/2003US6649633 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
11/18/2003US6649629 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/18/2003US6649619 Compounds
11/18/2003US6649613 Diacylhydrazine derivatives
11/18/2003US6649611 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
11/18/2003US6649608 Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors
11/18/2003US6649604 Analgesics; antidiabetic agents; antiinflamamtory agents
11/18/2003US6649601 Bisphosphonic compound
11/18/2003US6649366 Methods and compositions related to modulators of annexin and cartilage homeostasis
11/18/2003US6649172 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants
11/18/2003US6649168 Pharmaceutical compositions comprising TGF-beta
11/18/2003CA2265508C Bone morphogenetic protein-16 (bmp-16) compositions
11/13/2003WO2003093456A1 Soya cell strains with high isoflavone content
11/13/2003WO2003093314A2 Connective tissue stimulating peptides
11/13/2003WO2003093297A2 Protein kinase modulators and methods of use
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093245A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003WO2003093240A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003WO2003093238A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003092761A1 Surgical material comprising water glass fibres
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092681A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092666A1 Calcium-containing tissue strengthening agents and use thereof
11/13/2003WO2003092659A1 Oral dosage forms comprising fenofibrate
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
1 ... 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 ... 820